-
Clinical performance of non-invasive prenatal testing (NIPT) using targeted cell-free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studies.
Stokowski R, Wang E, White K, Batey A, Jacobsson B, Brar H, Balanarasimha M, Hollemon D, Sparks A, Nicolaides K, Musci TJ.
Prenat Diagn 2015;35:1243-6. pdf -
Screening for trisomies 21, 18 and 13 by cell-free DNA analysis of maternal blood at 10-11 weeks' gestation and the combined test at 11-13 weeks.
Quezada MS, Gil MM, Francisco C, Orosz G, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:36-41. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
Kagan KO, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:42-7. pdf -
Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis.
Gil MM, Quezada MS, Revello R, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:249-66. pdf -
A unified approach to risk assessment for fetal aneuploidies.
Wright D, Wright A, Nicolaides KH.
Ultrasound Obstet Gynecol 2015;45:48-54. pdf -
Frontomaxillary facial angle at 11 + 0 to 13 + 6 weeks: effect of plane of acquisition.
Plasencia W, Dagklis T, Pachoumi C, Kolitsi E, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;29:660-5. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
The mitral gap at 11 + 0 to 13 + 6 weeks: marker of trisomy 21 or artifact?
Maiz N, Dagklis T, Huggon I, Allan L, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:813-8. -
Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection.
Lo YM, Tsui NB, Chiu RW, Lau TK, Leung TN, Heung MM, Gerovassili A, Jin Y, Nicolaides KH, Cantor CR, Ding C.
Nat Med 2007;13:218-23. -
Dose dependency between cigarette consumption and reduced maternal serum PAPP-A levels at 11-13(+6) weeks of gestation.
Kagan KO, Frisova V, Nicolaides KH, Spencer K.
Prenat Diagn 2007;27:849-53. -
Ultrasound findings before amniocentesis in selecting the method of analysing the sample.
Kagan KO, Chitty LS, Cicero S, Eleftheriades M, Nicolaides KH.
Prenat Diagn 2007;27:34-9. -
Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?
Gerovassili A, Garner C, Nicolaides KH, Thein SL, Rees DC.
Prenat Diagn 2007;27:104-10. -
Nuchal translucency measurements for first-trimester screening: The 'price' of inaccuracy.
Evans MI, Van Decruyes H, Nicolaides KH.
Fetal Diagn Ther 2007;22:401-404. -
Frontomaxillary facial angle in chromosomally normal fetuses at 11 + 0 to 13 + 6 weeks.
Borenstein M, Persico N, Kaihura C, Sonek J, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:737-41. -
Megacystis at 10-14 weeks of gestation: chromosomal defects and outcome according to bladder length.
Liao AW, Sebire NJ, Geerts L, Cicero S, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;21:338-41. -
Cardiac expression of sarcoplasmic reticulum calcium ATPase in fetuses with trisomy 21 and trisomy 18 presenting with nuchal translucency.
von Kaisenberg CS, Huggon I, Hyett JA, Farzaneh F, Nicolaides KH.
Fetal Diagn Ther 1997:12:270-3. -
Fetal nuchal translucency thickness at 10-14 weeks gestation and congenital diaphragmatic hernia.
Sebire NJ, Snijders RJ, Davenport M, Greenough A, Nicolaides KH.
Obstet Gynecol 1997;90:943-6. -
Management of twin pregnancies with fetal trisomies.
Sebire NJ, Snijders RJM, Santiago C, Papapanagiotou G, Nicolaides KH.
BJOG 1997;104:220-2. -
Maternal serum free beta-hCG at 10 to 14 weeks of gestation in trisomic twin pregnancies.
Noble PL, Snijders RJ, Abraha HD, Sherwood RA, Nicolaides KH.
BJOG 1997;104:741-3. -
Urinary beta-core hCG: screening for aneuploidies in early pregnancy (11-14 weeks gestation)
Macintosh MC, Nicolaides KH, Noble P, Chard T, Gunn L, Illes R.
Prenat Diagn 1997;17:401-5.